IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.849
NA - Nord America 2.967
EU - Europa 1.165
SA - Sud America 645
Continente sconosciuto - Info sul continente non disponibili 101
AF - Africa 45
OC - Oceania 5
Totale 10.777
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 4.201
US - Stati Uniti d'America 2.823
IT - Italia 707
CN - Cina 598
BR - Brasile 494
BD - Bangladesh 368
HK - Hong Kong 245
VN - Vietnam 226
FR - Francia 112
DE - Germania 71
AR - Argentina 63
CA - Canada 59
GB - Regno Unito 58
IN - India 51
MX - Messico 45
NL - Olanda 37
FI - Finlandia 29
EC - Ecuador 28
ID - Indonesia 28
AT - Austria 26
EE - Estonia 25
ZA - Sudafrica 20
PK - Pakistan 18
UA - Ucraina 17
ES - Italia 14
JP - Giappone 14
PY - Paraguay 14
RU - Federazione Russa 14
CO - Colombia 13
IQ - Iraq 13
TR - Turchia 13
SA - Arabia Saudita 12
PH - Filippine 11
CL - Cile 8
PE - Perù 8
SE - Svezia 8
VE - Venezuela 8
BH - Bahrain 7
JM - Giamaica 7
UZ - Uzbekistan 6
BO - Bolivia 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
KE - Kenya 5
BA - Bosnia-Erzegovina 4
GT - Guatemala 4
HN - Honduras 4
IE - Irlanda 4
MA - Marocco 4
MD - Moldavia 4
MY - Malesia 4
NP - Nepal 4
PL - Polonia 4
QA - Qatar 4
RO - Romania 4
AU - Australia 3
AZ - Azerbaigian 3
CH - Svizzera 3
CW - ???statistics.table.value.countryCode.CW??? 3
EG - Egitto 3
KZ - Kazakistan 3
NI - Nicaragua 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
BE - Belgio 2
BG - Bulgaria 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GE - Georgia 2
HU - Ungheria 2
IR - Iran 2
KR - Corea 2
LT - Lituania 2
NG - Nigeria 2
PR - Porto Rico 2
SI - Slovenia 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BZ - Belize 1
CI - Costa d'Avorio 1
DM - Dominica 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
IL - Israele 1
JO - Giordania 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LB - Libano 1
Totale 10.668
Salva come PNG Salva come JPEG
Città #
San Jose 587
Ashburn 559
Singapore 486
Rome 362
Dallas 311
Hong Kong 238
Hefei 193
Beijing 170
Council Bluffs 156
Columbus 103
Lauterbourg 89
Phoenix 89
New York 83
Ho Chi Minh City 82
Santa Clara 76
Los Angeles 64
Boardman 55
Hanoi 48
São Paulo 43
Milan 41
Buffalo 31
Shanghai 31
Mexico City 30
Amsterdam 25
Munich 25
London 23
Denver 22
Naples 21
Chicago 20
Turku 19
Brooklyn 15
Sona 15
Rio de Janeiro 13
Toronto 13
Bari 12
Las Vegas 12
Philadelphia 12
Da Nang 11
Guayaquil 11
Vienna 11
Florence 10
Frankfurt am Main 10
Johannesburg 10
Montreal 10
Salvador 10
Belo Horizonte 9
Bologna 9
Boston 9
Orem 9
Turin 9
Brasília 8
Curitiba 8
Dhaka 8
Goiânia 8
Jinan 8
Kingston 8
Modena 8
Nuremberg 8
San Francisco 8
Charlotte 7
Chennai 7
Helsinki 7
Hải Dương 7
Seattle 7
Thái Bình 7
Tokyo 7
Atlanta 6
Campinas 6
Caxias do Sul 6
Guarulhos 6
Haiphong 6
Jeddah 6
Mumbai 6
Palermo 6
Santo André 6
Sorocaba 6
St Louis 6
Can Tho 5
Cordova 5
Genoa 5
Hamad Town 5
Kolkata 5
Louisville 5
Maceió 5
Madrid 5
Milwaukee 5
Pasadena 5
Quito 5
San José 5
Stockholm 5
The Dalles 5
Verona 5
Washington 5
Asunción 4
Biên Hòa 4
Blumenau 4
Bogor 4
Carapicuíba 4
Catania 4
Changsha 4
Totale 4.597
Salva come PNG Salva come JPEG
Nome #
112P Measuring time-toxicity and prognostic impact of hospital attendance in early phase cancer trials participants 348
1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy 329
1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC) 319
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC 313
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 287
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade 284
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung) 268
69P Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors 266
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 265
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan 263
96P Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens 248
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 243
Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment 239
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials 238
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 229
P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study 223
Association of Obesity With Survival Outcomes in Patients With Cancer 196
534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 186
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 177
OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 161
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 151
485 Impact of opioid signaling on the tumor microenvironment and clinical outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) 146
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 142
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 141
Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade 129
THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 129
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 121
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 119
T.07.3: CHARACTERISTICS AND OUTCOMES OF IMMUNOTHERAPYRELATED LIVER INJURY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA COMPARED TO PATIENTS WITH ADVANCED SOLID TUMOURS 116
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 111
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 100
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis 96
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer 96
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis 94
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer 91
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models 89
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 88
Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry 85
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 84
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials 80
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 80
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 79
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors 78
Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review 77
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 77
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes 73
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 73
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 72
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 70
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 68
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 68
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial 66
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 65
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 65
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival 64
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 64
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 63
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 62
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC 62
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 62
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 61
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 60
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) 59
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 59
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 58
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab 58
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 58
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 57
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry 57
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 56
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 56
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer 56
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 54
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 54
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer 53
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management 53
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 52
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice 52
Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival 50
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 50
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 50
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 49
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials 48
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view 48
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers 48
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens 47
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 47
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 47
Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review 46
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 45
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 44
Immunotherapy in Hepatocellular Carcinoma 43
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 43
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A "hypothesis-generator' study from clinical practice 42
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 42
Diabetes and Immune Checkpoint Inhibitors—Response 41
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry 41
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes 40
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 38
Hierarchical embedding attention for overall survival prediction in lung cancer from unstructured EHRs 36
Totale 10.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202227 0 0 0 0 3 0 0 0 4 0 0 20
2022/20232 0 0 0 0 1 0 0 0 0 0 1 0
2023/2024102 0 10 19 14 7 29 2 3 6 5 5 2
2024/20254.356 26 19 72 19 12 30 148 64 244 276 1.793 1.653
2025/20265.073 298 215 512 637 253 236 1.042 219 396 408 584 273
2026/20271.217 103 412 385 317 0 0 0 0 0 0 0 0
Totale 10.777